Phenotypes associated with this allele

• Allele Symbol: Tagln^{tm1(cre/ERT2)Feil}
• Allele Name: targeted mutation 1, Robert Feil
• Allele ID: MGI:2389040
• Summary: 3 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Mylk^tm1Mzhu/Mylk^tm1Mzhu Tagln^tm1(cre/ERT2)Feil/?	involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6	MGI:3820693
cn2	Stk11^tm1.1Rdp/Stk11^+ Tagln^tm1(cre/ERT2)Feil/Tagln^+	involves: 129S/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL	MGI:3814821
cn3	Stk11^tm1.1Rdp/Stk11^tm1.1Rdp Tagln^tm1(cre/ERT2)Feil/Tagln^+	involves: 129S/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL	MGI:3814824

Genotype
MGI:3820693

cn1

• Allelic Composition: Mylk^tm1Mzhu/Mylk^tm1Mzhu; Tagln^{tm1(cre/ERT2)Feil}/?
• Genetic Background: involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:141907 )

• all mice die within 17 days of the onset of tamoxifen treatment with a paralytic gut

growth/size/body

distended abdomen ( J:141907 )

• enlarged abdomen after 5 consecutive days of tamoxifen injections

renal/urinary system

abnormal urinary bladder physiology ( J:141907 )

• after 5 consecutive days of tamoxifen injections

ischuria ( J:141907 )

• retention of urine late in the course of tamoxifen treatments

digestive/alimentary system

abnormal intestine morphology ( J:141907 )

abnormal intestinal smooth muscle morphology ( J:141907 )

• smooth muscle layers of the jejunum are thickened due to enlarged smooth muscle cells

• enlarged muscle layers in the ileum but to a lesser extent than in jejunum

distended ileum ( J:141907 )

• grossly distended after 5 consecutive days of tamoxifen injections

• contains abundant liquid

distended jejunum ( J:141907 )

• grossly distended after 5 consecutive days of tamoxifen injections

• contains abundant liquid

• becomes dilated late in tamoxifen treatment

abnormal digestive system physiology ( J:141907 )

• anal sphincter muscle tension is reduced after 5 consecutive days of tamoxifen injections

abnormal defecation ( J:141907 )

• reduced excretion of feces after 5 consecutive days of tamoxifen injections

abnormal gastrointestinal motility ( J:141907 )

• abnormal gastrointestinal motility after 5 consecutive days of tamoxifen injections

abnormal intestinal peristalsis ( J:141907 )

• contractile tension significantly reduced

• tension development of ileal and jejunal strips is 13% of controls in response to KCl

• 20-28% tension response to acetylcholine which is abolished by atropine treatment

• peristaltic frequency of the ileum increased by 30%

small intestinal inflammation ( J:141907 )

• mucosal inflammation

• elevated bacterial counts

skeleton

abnormal vertebral column morphology ( J:141907 )

• severe spinal sinuosity after 5 consecutive days of tamoxifen injections

behavior/neurological

decreased food intake ( J:141907 )

• reduced food intake after 5 consecutive days of tamoxifen injections

cardiovascular system

decreased systemic arterial blood pressure ( J:141907 )

• after 5 consecutive days of tamoxifen injections

decreased systemic arterial diastolic blood pressure ( J:141907 )

decreased systemic arterial systolic blood pressure ( J:141907 )

immune system

small intestinal inflammation ( J:141907 )

• mucosal inflammation

• elevated bacterial counts

muscle

abnormal intestinal smooth muscle morphology ( J:141907 )

• smooth muscle layers of the jejunum are thickened due to enlarged smooth muscle cells

• enlarged muscle layers in the ileum but to a lesser extent than in jejunum

abnormal intestinal peristalsis ( J:141907 )

• contractile tension significantly reduced

• tension development of ileal and jejunal strips is 13% of controls in response to KCl

• 20-28% tension response to acetylcholine which is abolished by atropine treatment

• peristaltic frequency of the ileum increased by 30%

Genotype
MGI:3814821

cn2

• Allelic Composition: Stk11^tm1.1Rdp/Stk11⁺; Tagln^{tm1(cre/ERT2)Feil}/Tagln⁺
• Genetic Background: involves: 129S/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL

mortality/aging

premature death ( J:134476 )

• almost 50% of tamoxifen-treated animals die by 18 months from gastrointestinal obstruction (average lifespan 13.5 months); widespread gastrointestinal polyposis is found at time of necropsy

digestive/alimentary system

digestive/alimentary phenotype ( J:134476 )

N • with 2 intraperitoneal injections of tamoxifen at 6 weeks of age, no abnormalities are seen at 3 and 8 months of age

gastrointestinal tract polyps ( J:134476 )

• at 11 months, gastrointestinal tract polyps are observed in <60% of tamoxifen-treated animals

• average polyp size is smaller than in Stk11^tm1.2Rdp/+ mice at 11 months

increased gastrointestinal tumor incidence ( J:134476 )

• tumor formation (polyposis) in the gastrointestinal tract is increased greatly relative to controls

• tumors are characterized by a smooth muscle core, abundant stroma and hyperplastic epithelia without dysplasia

intestinal obstruction ( J:134476 )

• at 11 months, mice present with severe gastrointestinal obstruction

neoplasm

increased gastrointestinal tumor incidence ( J:134476 )

• tumor formation (polyposis) in the gastrointestinal tract is increased greatly relative to controls

• tumors are characterized by a smooth muscle core, abundant stroma and hyperplastic epithelia without dysplasia

Genotype
MGI:3814824

cn3

• Allelic Composition: Stk11^tm1.1Rdp/Stk11^tm1.1Rdp; Tagln^{tm1(cre/ERT2)Feil}/Tagln⁺
• Genetic Background: involves: 129S/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL

digestive/alimentary system

gastrointestinal tract polyps ( J:134476 )

• 75% of tamoxifen-treated animals develop gastrointestinal polyposis by 11 months

• average size of polyps is comparable to that seen in double heterozygotes

increased gastrointestinal tumor incidence ( J:134476 )

• tumor formation (polyposis) in the gastrointestinal tract is increased greatly relative to controls

neoplasm

increased gastrointestinal tumor incidence ( J:134476 )

• tumor formation (polyposis) in the gastrointestinal tract is increased greatly relative to controls